• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
171963 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  + Q$ i0 ]4 n+ I4 @$ d) }$ H

* z3 P+ M  f8 r6 {; F5 H# g+ `" @" Z1 w5 a+ A' W7 B# t
Sub-category:
: D9 o3 [+ |. a4 ^; UMolecular Targets
4 ~9 W* m; y6 l" `  m4 g4 E* S+ Z1 i# y" G' T
) @6 F* [6 L" n9 H
Category:% a$ n' V$ w# ?4 M
Tumor Biology
1 o; @% S6 J& P& [- e* W2 s; \# s- `0 A

& P( R- D: ^: W) x* kMeeting:
$ Q! ?; {+ f( ]/ ^& C2 {, x+ @2011 ASCO Annual Meeting ( t+ i2 a9 G: ]0 L. F, G$ d
; Z6 ^7 ?4 \; J# z3 \4 O0 U. J' C

! l; ]$ f* P) s* |  F7 T& m; bSession Type and Session Title:
% e  T2 J% [+ C: M/ F5 X8 WPoster Discussion Session, Tumor Biology
7 Q# p0 l4 y! ?/ V0 R1 P) S! a1 W$ |0 k- ~: T* r% g5 n

- g5 t/ _8 ~; m5 P$ sAbstract No:
' G( S& v, z% m; g* \" n10517 ' N* O# m4 d6 m( r$ o2 M% d

+ ?3 a5 b1 z* G) a+ D
1 s" ?$ `2 v: n) p/ @Citation:! c6 `4 i) }1 I  Z* w* {% n
J Clin Oncol 29: 2011 (suppl; abstr 10517) 1 }2 [5 G( b0 H
3 |2 g  J# F" P: w) K) n2 q' j
2 S% q4 a4 _! I1 [  E/ b2 [$ |
Author(s):( w) q1 @5 a8 O- G1 w  X
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 3 I/ o8 d/ [. c+ v" ]8 I! M9 B

* l7 _  h; w/ r- r' A6 g  b* u# z& H8 i! ?7 j" y# g
- N/ C. ~8 u/ ]- {9 o  ~- O# f
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
/ i9 X) i7 u: |5 g
" V( I% n' O5 K0 _Abstract Disclosures
. j$ \5 _9 n9 l/ V
9 z5 Y' j  O  U  {; }  tAbstract:
1 y5 r2 M2 p* L0 ]
' u8 M. I( a; d$ L4 D' D& e! e( Z' \
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation." M6 F8 n# g0 b$ n1 A

; ~9 C; l2 F: I2 n 0 d: H6 P7 n# M' ]8 T  ~
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 3 n, }- I4 a& A9 N# I
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

0 Z+ J5 @8 e" e" E7 f* e化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
5 O+ p. g3 H3 B8 C易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。" X: d4 {: b! {2 K2 G2 S; \
ALK一个指标医院要900多 ...

& E9 X: n6 F6 P- \0 n+ e" m平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?' R3 ~/ f$ g$ H  |9 W3 s; i
% ]1 H( F" x( c2 ~  i1 b! ?
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表